The estimated Net Worth of Michael P Smith is at least $4.56 Миллион dollars as of 15 March 2021. Mr. Smith owns over 5,218 units of Zogenix Inc stock worth over $202,368 and over the last 8 years he sold ZGNX stock worth over $0. In addition, he makes $4,358,280 as Chief Financial Officer, Executive Vice President и Treasurer at Zogenix Inc.
Sign up
Mr. Smith ZGNX stock SEC Form 4 insiders trading
Michael has made over 7 trades of the Zogenix Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,218 units of ZGNX stock worth $139,216 on 15 March 2021.
The largest trade he's ever made was exercising 22,500 units of Zogenix Inc stock on 2 January 2020 worth over $232,875. On average, Michael trades about 5,990 units every 56 days since 2017. As of 15 March 2021 he still owns at least 7,585 units of Zogenix Inc stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Smith biography
Michael P. Smith serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. Mr. Smith has served as our Executive Vice President, Chief Financial Officer, Treasurer and Secretary since January 2017. From January 2015 through December 2016, Mr. Smith served as Chief Financial Officer of Raptor Pharmaceutical Corp., a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare diseases that was acquired by Horizon Pharma plc. in October 2016. In this role, he was responsible for the finance, accounting, corporate development, corporate strategy, intellectual property, and information management business functions. From May 2012 to January 2015, Mr. Smith served as Chief Financial and Business Advisor at Catalyst Biosciences. Prior to that role, from September 2010 to April 2011, he was Vice President of Business Development at iPierian, Inc., and from June 2006 to July 2009, he served as Head of Business Development and Chief Financial Officer of Memory Pharmaceuticals Corporation. Mr. Smith received his B.S. in Commerce from the University of Virginia and his M.B.A. from the Haas School of Business at the University of California, Berkeley.
What is the salary of Michael Smith?
As the Chief Financial Officer, Executive Vice President и Treasurer of Zogenix Inc, the total compensation of Michael Smith at Zogenix Inc is $4,358,280. There are 2 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.
How old is Michael Smith?
Michael Smith is 51, he's been the Chief Financial Officer, Executive Vice President и Treasurer of Zogenix Inc since 2020. There are 21 older and 1 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
What's Michael Smith's mailing address?
Michael's mailing address filed with the SEC is 5858 Horton St #455, Emeryville, CA 94608, USA.
Insiders trading at Zogenix Inc
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo и Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
What does Zogenix Inc do?
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
What does Zogenix Inc's logo look like?
Complete history of Mr. Smith stock trades at Zogenix Inc
Zogenix Inc executives and stock owners
Zogenix Inc executives and other stock owners filed with the SEC include:
-
Stephen Farr,
President, Chief Executive Officer, Director -
Bradley Galer,
Executive Vice President, Chief Medical Officer -
Michael Smith,
Chief Financial Officer, Executive Vice President, Treasurer -
Gail Farfel,
Executive Vice President, Chief Development Officer -
Ashish Sagrolikar,
Executive Vice President, Chief Commercial Officer -
Dr. Stephen J. Farr,
Co-Founder, CEO, Pres & Director -
Shawnte M. Mitchell,
Exec. VP, Gen. Counsel & Sec. -
Dr. Bradley S. Galer,
Exec. VP & Chief Medical Officer -
Dr. Gail M. Farfel,
Exec. VP & Chief Devel. Officer -
Michael P. Smith,
Exec. VP, CFO & Treasurer -
Ashish M. Sagrolikar,
Exec. VP & COO -
Cam Garner,
Independent Chairman of the Board -
Erle Mast,
Independent Director -
Louis Bock,
Independent Director -
Mark Wiggins,
Independent Director -
James Breitmeyer,
Independent Director -
Renee Tannenbaum,
Independent Director -
Denelle Waynick,
Independent Director -
Mary Stutts,
Independent Director -
Caroline Loewy,
Independent Director -
Shawnte Mitchell,
Executive Vice President, General Counsel, Secretary -
Stephen H. Jenner,
VP of Marketing -
Bret E. Megargel,
VP of Corp. Devel. -
Melinda Baker,
Sr. Director of Corp. Communications -
Jeff D. Durflinger,
VP of Technical Operations & Product Supply -
Ann D Rhoads,
EVP, CFO, Treasurer & Sec. -
Thierry J.P. Darcis,
EVP / General Manager, Europe -
Venture Partners Ii, Lp Sca...,
-
Growth Partners Ii L P Chic...,
-
Advisors Llcperceptive Life...,
-
Roger Hawley,
Chief Executive Officer -
James C Blair,
Director -
Richard Scott Shively,
Chief Commercial Officer -
Nicole Vitullo,
10% owner -
Ken Haas,
Director -
Cynthia Y Robinson,
Chief Development Officer -
Brian K Halak,
10% owner -
Arda Phd Minocherhomjee,
Director -
Kurt Wheeler,
Director -
Kathleen K Schoemaker,
10% owner -
Lifesciences I, L.P.Clarus ...,
-
Parters Vii L P Domain,
10% owner -
Vi Associates, L.P. Dp,
10% owner -
Venture Partners Ii, Lp Sca...,
-
Brian H Dovey,
10% owner -
Partners Vi, L.P. Domain,
10% owner -
Jesse I Treu,
10% owner -
Mcnerney & Partners Lp Thom...,
-
Vii Associates Lp Dp,
10% owner -
Lifesciences I, L.P.Clarus ...,